Last reviewed · How we verify
Investigator's Choice Treatment — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Investigator's Choice Treatment (Investigator's Choice Treatment) — Shanghai Runshi Pharmaceutical Technology Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Investigator's Choice Treatment TARGET | Investigator's Choice Treatment | Shanghai Runshi Pharmaceutical Technology Co., Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Investigator's Choice Treatment CI watch — RSS
- Investigator's Choice Treatment CI watch — Atom
- Investigator's Choice Treatment CI watch — JSON
- Investigator's Choice Treatment alone — RSS
Cite this brief
Drug Landscape (2026). Investigator's Choice Treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/investigator-s-choice-treatment. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab